Between COVID-19 severity and its prevention – what should rheumatologists be aware of?

Joanna Makowska; Filip Styrzyński

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology Supplements

Bieżący suplement Archiwum Reumatologia

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla reumatologów!

www.ereumatologia.pl

Wyszukiwanie

1/2021

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Between COVID-19 severity and its prevention – what should rheumatologists be aware of?

Joanna Makowska

¹

,

Filip Styrzyński

¹

Department of Rheumatology, Medical University of Lodz, Poland

Data publikacji online: 2021/09/08

Pełna treść artykułu Pobierz cytowanie

A year has passed since the unprecedented eruption of SARS-CoV-2 infections affected almost all countries around the world. Rheumatic patients represent a numerous group of people in which the immune system is impaired both by chronic immunosuppressive treatment and by the disease itself. For this reason doctors are worried about the optimal management and how to prevent the exacerbation of autoimmune systemic diseases.

Recently, a few important studies have been published regarding the risk of a severe course of COVID amongst rheumatic patients, parallel to the dynamically ongoing worldwide vaccination process as never seen before.

Between COVID-19 severity and its prevention – what should rheumatologists be aware of?

Joanna Makowska 1 , Filip Styrzyński 1

Joanna Makowska

¹

,

Filip Styrzyński

¹